Global drug giant Pfizer has made an offer of 675.00 rupees per share, or 6.8 billion ($137.7 million) rupees in total, to increase the stake in its indirect Indian subsidiary to 75% from the current level of 41%. Shares in the division rose 9% to 677 rupees in morning trading on the day of the news, April 13.
To adhere to Indian law, Pfizer will make a public announcement of the deal before it makes the offer for the additional 34% of its subsidiary through the Bombay Stock Exchange and the National Stock Exchange of India. The action will open in June.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze